First-line treatment for severe aplastic anemia: transplantation or ATG-based therapy

A patient with newly diagnosed severe aplastic anemia may be advised to pursue transplantation or to begin ATG-based medical treatment. The choice cannot rest only on “transplant can cure” or “medicines do not need a donor.” It depends on whether a donor is genuinely usable, what the patient can tolerate, how long preparation will take, and whether support can continue reliably. Recommendations built on different assumptions can reasonably differ.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

First establish the diagnosis. Is acquired immune-mediated aplastic anemia adequately supported, or could hypocellular myelodysplastic neoplasia or inherited marrow failure alter the recommendation? Specify which unresolved result could change treatment and how it will be obtained promptly. Essential support continues while pathology questions are resolved.
The risk from low counts does not vanish when disease treatment starts. Arrange the laboratory, transfusion service, infection prevention, and fever response in advance. The transition from inpatient ATG to outpatient care is a common point of confusion: a discharge document should clearly identify continuing medicines, who reviews results, and when the patient returns.
The receiving center should first review records and confirm acceptance, the proposed medicine or donor pathway, and any missing prerequisites. Record assessment, on-arrival review, ATG treatment or transplant preparation, and observation near the center are separate time periods. After transplantation, discharge does not automatically imply that international travel is appropriate; early surveillance needs access to a service that can manage complications. Suárez-Lledó and Rovira: Short- and Long-Term Controls After HCT, EBMT Handbook 2024

Quick answer

Full guide

The 2026 ASH and 2024 BSH guidance place transplantation and immunosuppression in defined patient settings. A hospital still needs to explain why its proposal fits this individual. The patient should receive a plan for preparation, initial care, and an inadequate response, rather than only a drug name or a transplant appointment. ASH 2026 aplastic anemia guidelines BSH 2024 adult aplastic anaemia guideline

Confirm the facts that determine the starting treatment

First establish the diagnosis. Is acquired immune-mediated aplastic anemia adequately supported, or could hypocellular myelodysplastic neoplasia or inherited marrow failure alter the recommendation? Specify which unresolved result could change treatment and how it will be obtained promptly. Essential support continues while pathology questions are resolved.

Next assess the immediate danger. Serious infection, bleeding, and symptomatic anemia influence whether the patient can wait and where waiting is safe. Waiting for a donor or drug does not mean going home without a protection plan. The team should identify responsibility for transfusions, infection treatment, repeat counts, and problems outside clinic hours.

Donor information must be concrete. HLA findings, donor health, collection feasibility, and timing matter. A willing relative is not necessarily an available matched donor. If an unrelated search is needed, ask its actual stage and whether a delay would change the initial strategy. Early typing preserves an option without taking the consent decision away from the patient.

Finally assess treatment tolerance and practicality: kidney, liver, heart and lung function, other illness, fitness, and caregiving. Age contributes but does not replace those details. Difficulty reaching emergency care, attending blood tests, or following medicines should be disclosed before selection, because those problems affect the safety of the treatment being proposed. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024

When transplantation deserves an early discussion

A younger, medically suitable person with an appropriate donor available promptly should usually receive an early formal transplant assessment. The final decision still depends on donor type and individual risk. A matched sibling, matched unrelated donor, and haploidentical donor do not create identical treatment situations, and results from one cannot simply be applied to all.

Transplantation establishes donor-derived blood production rather than surgically removing the patient’s marrow. The process includes conditioning, infection prevention, engraftment monitoring, and prevention of graft-versus-host disease. Because aplastic anemia is nonmalignant, a graft-versus-leukemia effect is not required. Avoiding rejection and immune complications is therefore central to the discussion.

Ask why the proposed donor was selected, what risk accompanies the waiting period, how the cell source is chosen, and what complications the center sees in comparable aplastic-anemia patients. A general success rate that omits patient ages, donor details, and the endpoint measured is not enough for an individual decision. Both the opportunity for durable recovery and serious early complications need explanation.

Possible inherited marrow failure must be addressed before clearing a related donor or finalizing conditioning. Some patients are unusually sensitive to standard damaging treatment, while an apparently healthy relative may share the underlying condition. Genetic evaluation is intended to modify medical decisions; unresolved concerns should not be omitted merely to preserve a convenient admission date. Diaz-de-Heredia et al.: Hereditary Bone Marrow Failure Syndromes, EBMT Handbook 2024

What ATG-based treatment is intended to do

Immunosuppression reduces the attack on remaining blood-forming cells so that production can recover. A common foundation is ATG plus cyclosporine, with eltrombopag added where suitable. Starting this pathway does not require an identified donor, but it does require regulated medicines, management of infusion reactions, and sustained oral treatment and support afterward.

ATG is not one interchangeable product. Horse, rabbit, and other related preparations have different evidence, doses, and clinical uses. “ATG treatment” on a quotation is insufficient: ask for the preparation and the reason the center recommends it. If supply changes, the clinician should reassess the regimen rather than allowing a patient-led substitution based on price or volume.

The randomized RACE study supports improved hematologic response when eltrombopag is added to standard immunosuppression. The result belongs to the studied population and combination. It does not establish that eltrombopag alone is adequate, that everyone responds, or that transfusions stop immediately. Individual response remains a question for sustained blood-count and support-requirement assessment. Peffault de Latour et al.: Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia, 2022

Eltrombopag should not be added independently whenever platelets are low. The starting schedule and dose depend on the clinical setting and actual product instructions. Liver monitoring is needed, and food or supplements containing calcium, iron, or other minerals can affect absorption. International evidence does not replace checking Chinese approval, permitted ages, and hospital supply for the intended product. MedlinePlus: Eltrombopag

Cyclosporine generally continues beyond the ATG admission. Baseline renal function and blood pressure inform treatment, followed by protocol-based monitoring and drug levels when appropriate. Ask about sampling instructions and record dosing honestly rather than stopping or adding doses to improve an anticipated result. A new prescription for another condition can change cyclosporine exposure and should be reported. MedlinePlus: Cyclosporine

Plan the first months, not only the first admission

The risk from low counts does not vanish when disease treatment starts. Arrange the laboratory, transfusion service, infection prevention, and fever response in advance. The transition from inpatient ATG to outpatient care is a common point of confusion: a discharge document should clearly identify continuing medicines, who reviews results, and when the patient returns.

Red cells and platelets address different needs and can require different scheduling or component selection. Tell the transfusion service about immunosuppression and potential transplantation. Previous antibodies, reactions, and component records help provide suitable support. Continuing transfusion early in the course is not independently evidence that first-line treatment has failed. Schrezenmeier et al.: Transfusion Support, EBMT Handbook 2024

Infection and treatment timing sometimes require a joint decision. Severe infection can make transplantation or immunosuppression more hazardous, while prolonged profound neutropenia can make infection difficult to control. Ask the team to explain the chosen sequence, what findings would permit progression, and what would require a change. Neither an indefinite instruction to wait nor an unchanged admission schedule adequately addresses a changing clinical problem.

A practical household calendar can list actual tasks: medicines, counts or drug-level tests, clinic visits, expected support, and contact details. If food timing, transport, and doses conflict, nurses and pharmacists may help create a workable arrangement. Detecting these barriers before treatment is preferable to discovering them after missed medicines or an unreviewed abnormal result.

Establish when the second-line conversation will occur

Agree on response assessment when initial treatment begins. Recovery after immunosuppression is often judged over months, so persistently low counts shortly after ATG are not enough to declare failure. Continuing infection, bleeding, or extremely low neutrophils also cannot justify an unlimited wait based only on the possibility of a delayed response. There should be a boundary and a team responsible for deciding.

ASH 2026 guidance emphasizes timely second-line treatment for nonresponders, with earlier decisions potentially needed in very severe disease. The individual time point depends on the clinical trajectory, usable donors, and alternative treatment. Before switching, review the diagnosis, adequacy of the first regimen, toxicity-related limitations, and any new marrow or genetic evidence.

Even a responder can later relapse or develop clonal changes. An initial decision should therefore include maintenance, conditions for tapering, and a plan for renewed cytopenias. Long-term follow-up studies help explain why an early response is a meaningful milestone rather than the end of all clinical questions. Patel et al.: Long-term outcomes after immunosuppression and eltrombopag

Compare differing recommendations on equivalent terms

Set the proposals alongside each other using the starting regimen, ATG preparation, confirmed donor status, acceptable delay, support location, response definition, and later options. If one differs because a medicine or transplant approach is unavailable there, identify that resource constraint. If the difference reflects an assessment of personal risk, ask for the supporting evidence. This provides a more actionable answer than ranking hospitals as more or less advanced.

Patient priorities also matter once the medically feasible options have been explained. Some people prioritize the possibility of early definitive restoration; others need detailed discussion of chronic immune complications or face substantial caregiving constraints. The clinician should not ask the patient to choose blindly between unexplained technical names. A second opinion is best supplied with the same original marrow, blood-count, and donor information.

Confirm the details before starting treatment in China

The receiving center should first review records and confirm acceptance, the proposed medicine or donor pathway, and any missing prerequisites. Record assessment, on-arrival review, ATG treatment or transplant preparation, and observation near the center are separate time periods. After transplantation, discharge does not automatically imply that international travel is appropriate; early surveillance needs access to a service that can manage complications. Suárez-Lledó and Rovira: Short- and Long-Term Controls After HCT, EBMT Handbook 2024

Request a renminbi quotation for the selected pathway. For immunosuppression, list the ATG product and administration, continuing cyclosporine and eltrombopag, monitoring, blood products, and infection care. A transplant quote also needs donor evaluation, collection, cell processing, conditioning, admission, and early follow-up. Confirm international self-pay status, inclusions, and conditions for revision. An individualized hospital total has not been verified for this guide, so unknown prices and quantities remain awaiting confirmation rather than being replaced by broad internet figures.